Ahmedabad-based formulation and API maker supplying regulated (US/Canada/UK), emerging-market and Indian hospital (branded generics) pharma channels.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 9 | 10 | 31 | 46 | 46 | 46 |
| Reserves | 28 | 36 | 174 | 740 | 768 | 888 |
| Borrowings | 15 | 63 | 258 | 315 | 241 | 342 |
| Other Liabilities | 8 | 23 | 160 | 126 | 233 | 328 |
| Total Liabilities | 59 | 131 | 622 | 1.2k | 1.3k | 1.6k |
| AssetsFixed Assets | 7 | 27 | 235 | 301 | 540 | 755 |
| CWIP | 8 | 34 | 97 | 172 | 16 | 17 |
| Investments | 15 | 16 | 0 | 0 | 2 | 4 |
| Other Assets | 29 | 53 | 289 | 754 | 731 | 827 |
| Total Assets | 59 | 131 | 622 | 1.2k | 1.3k | 1.6k |
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ActivitiesCash from Operating | -10 | -1 | -26 | -46 | 62 |
| Cash from Investing | -24 | -48 | -54 | -429 | -121 |
| Cash from Financing | 36 | 46 | 87 | 573 | -1 |
| SummaryCapital Expenditure | — | — | — | — | — |
| Free Cash Flow | -21 | -48 | -78 | -203 | -203 |
| FCF Margin | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (40.9×) and current (57.0×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 118.4% growth and a 41× exit, ₹1405 only delivers your return if you pay ₹32,459. The price is currently baking in 25% growth.
EPS grows 118.4%/yr for 5 years, then fades to 6% over 2, exits at 41×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 118.4% | 53.84 |
| FY28 | 118.4% | 117.58 |
| FY29 | 118.4% | 256.79 |
| FY30 | 118.4% | 560.83 |
| FY31 | 118.4% | 1224.84 |
| FY32 | 62.2% ·fade | 1986.69 |
| FY33 | 6.0% ·fade | 2105.90 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.